Table 2.

Objective Responses With Venetoclax Monotherapy as Assessed by the Investigator

	Patients who received ibrutinib as the last prior BCRi
	Main cohort n=43	Expansion cohort n=48	All patients N=91
ORR, n (%); [95% CI]	30 (70); [54%; 83%]	29 (60); [43%, 72%]	59 (65); [53%, 74%]
CR/CRi, n (%)	4 (9)	4 (8)	8 (9)
nPR, n (%)	2 (5)	1 (2)	3 (3)
PR, n (%)	24 (56)	24 (48)	48 (52)
SD, n (%)	8 (19)	14 (29)	22 (24)
PD, n (%)	1* (2)	4* (8)	5 (6)
Discontinued prior to response assessment	4 (9)	2 (4)	6 (7)

BCRi, B-cell receptor pathway inhibitor; ORR, objective response rate = complete response (CR) + complete response with incomplete bone marrow recovery (CRi) + nodular partial remission (nPR) + partial remission (PR); SD, stable disease; PD, disease progression.

^*Chronic lymphocytic leukaemia progressed, and patients discontinued because of progression.